Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib
Joint Authors
Kasper, Bernd
Pilz, Lothar R.
Sachpekidis, Christos
Hohenberger, Peter
Strauss, Ludwig G.
Dimitrakopoulou-Strauss, Antonia
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-05-16
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
We used 2-deoxy-2-[18F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate patients with desmoid tumors undergoing therapy with imatinib.
The study included 22 patients with progressive disease (PD) of a biopsy proven desmoid tumor treated orally with imatinib 800 mg daily.
Patients were examined using PET prior to onset of therapy and during treatment.
Restaging was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI).
Outcome of 22 evaluable patients was as follows: five patients with partial response (PR); twelve patients with stable disease (SD) accounting for 77% with non-progressive disease; five patients showed PD.
A 30% decrease of the mean average standardized uptake value (SUV) of sequential PET examinations could be demonstrated; no patient demonstrated a substantial increase in SUV.
Patients with PR/SD were matched to a group of nonprogressive disease and tested versus PD.
The initial average SUV and SUVmax seem to be candidates for a response prediction with an approximate P-value of 0.06553 and 0.07785, respectively.
This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued.
American Psychological Association (APA)
Kasper, Bernd& Dimitrakopoulou-Strauss, Antonia& Pilz, Lothar R.& Strauss, Ludwig G.& Sachpekidis, Christos& Hohenberger, Peter. 2013. Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. BioMed Research International،Vol. 2013, no. 2013, pp.1-7.
https://search.emarefa.net/detail/BIM-1030496
Modern Language Association (MLA)
Kasper, Bernd…[et al.]. Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. BioMed Research International No. 2013 (2013), pp.1-7.
https://search.emarefa.net/detail/BIM-1030496
American Medical Association (AMA)
Kasper, Bernd& Dimitrakopoulou-Strauss, Antonia& Pilz, Lothar R.& Strauss, Ludwig G.& Sachpekidis, Christos& Hohenberger, Peter. Positron Emission Tomography as a Surrogate Marker for Evaluation of Treatment Response in Patients with Desmoid Tumors under Therapy with Imatinib. BioMed Research International. 2013. Vol. 2013, no. 2013, pp.1-7.
https://search.emarefa.net/detail/BIM-1030496
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1030496